Ex vivo propagation of infectious sheep scrapie agent in heterologous epithelial cells expressing ovine prion protein

Didier Vilette, Olivier Andréoletti, M.F. Madelaine, Jean-Luc Vilotte, S. Lehmann, Hubert Laude

To cite this version:


HAL Id: hal-02680606
https://hal.inrae.fr/hal-02680606
Submitted on 31 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - ShareAlike 4.0 International License
Ex vivo propagation of infectious sheep scrapie agent in heterologous epithelial cells expressing ovine prion protein

D. Vilette*,†, O. Andreoletti‡, F. Archer*, M. F. Madelaine*, J. L. Villette§, S. Lehmann¶, and H. Laude*

*Unité de Virologie Immunologie Moléculaires and ‡Laboratoire de Génétique Biochimique et Cytogénétique, Institut National de la Recherche Agronomique, 78350 Jouy-en-Josas, France; †UMR Institut National de la Recherche Agronomique–Ecole Nationale Vétérinaire de Toulouse 959 de Physiopathologie Infectieuse et Parasitaire des Ruminants, Ecole Nationale Vétérinaire de Toulouse, 31076 Toulouse, France; and ¶Institut de Génétique Humaine, Centre National de la Recherche Scientifique, 34396 Montpellier, France

Edited by Charles Weissmann, Imperial College of Science, Technology, and Medicine, London, United Kingdom, and approved January 11, 2001 (received for review July 20, 2000)

Transmissible spongiform encephalopaties, or prion diseases, are fatal degenerative disorders of the central nervous system that affect humans and animals. Prions are nonconventional infectious agents whose replication depends on the host prion protein (PrP). Transmission of prions to cultured cells has proved to be a particularly difficult task, and with a few exceptions, their experimental propagation relies on inoculation to laboratory animals. Here, we report on the development of a permanent cell line supporting propagation of natural sheep scrapie. This model was obtained by stable expression of a tetracycline-regulatable ovine PrP gene in a rabbit epithelial cell line. After exposure to scrapie agent, cultures were repeatedly found to accumulate high levels of abnormal PrP (PrPres). Cell extracts induced a scrapie-like disease in transgenic mice overexpressing ovine PrP. These cultures remained healthy and stably infected upon subpassaging. Such data show that (i) cultivated cells from a nonneuronal origin can efficiently replicate prions; and (ii) species barrier can be crossed ex vivo through the expression of a relevant PrP gene. This approach led to the ex vivo propagation of a natural transmissible spongiform encephalopathy agent (i.e., without previous experimental adaptation to rodents) and might be applied to human or bovine prions.

Transmissible spongiform encephalopathies (TSEs) are fatal infectious neurodegenerative diseases of the central nervous system (1, 2). These naturally occurring human and animal disorders include Creutzfeldt–Jakob disease, scrapie in sheep and goats, and the more recently observed bovine spongiform encephalopathy in cattle. In most cases, these diseases are associated with the accumulation of an abnormal pathological isoform of the host-derived prion protein (PrP).

PrP is a glycoprotein located at the cell surface, where it is bound by a glycosyl-phosphatidylinositol anchor (3). It is present in a variety of tissues (4, 5) and is mainly expressed in the central nervous system, particularly in the neurons (6). Although the precise physiological function of PrP remains to be established, a wealth of experimental data demonstrates its essential role in the precise physiological function of PrP remains to be established, a nervous system, particularly in the neurons (6). Although the variety of tissues (4, 5) and is mainly expressed in the central nervous system (1–3). According to the protein-only hypothesis (19), the TSE infectious agent is PrPres itself or a precursor of it. However, although PrP and its conversion are recognized as key events in TSE replication and pathogenesis, formal proof that abnormal PrP is the actual transmissible agent has yet to be obtained.

Only a few cell culture models permissive to prion replication are available to date (3). Mouse neuroblastoma N2a, the more intensively used cell line to date (20), and other infectable rodent cell cultures including PC12 rat pheochromocytoma cells (21) and the GT-1 hypothalamic neuronal cell line (22) have provided some valuable insights into the biogenesis of PrPres in infected cells (3). Additionally, these and the persistently infected SMB murine cell line (23), have been used to screen potential drugs for their ability to inhibit PrPres accumulation (24–27). Recently, apoptosis was demonstrated in infected GT-1 cells (22), suggesting that this model could be relevant to study neurodegenerative changes in TSE. However, a common feature of the above cell lines is to support propagation of TSE strains experimentally adapted to rodents only. So far, despite repeated attempts (28), relevant cell culture models for strains from naturally occurring TSE diseases such as scrapie, bovine spongiform encephalopathy, and Creutzfeldt–Jakob disease are lacking, although propagation of human prions was reported on one occasion (29).

In this paper, we report the characteristics of a cell model in which a prototypical, naturally occurring animal TSE, sheep scrapie, can actively replicate.

Materials and Methods

Vector Construction and Transfection of RK13 Rabbit Cell Line. The complete coding sequence of the VRQ allele (Val-136, Arg-154, and Gln-171) of ovine PrP was PCR-cloned in the pTRE plasmid (CLONTECH). The PrP ORF was verified by DNA sequencing, and the resulting plasmid was transfected by the Lipofectamine method (GIBCO/BRL) into rabbit kidney epithelial cells (30). Stable transfectants were selected in the presence of puromycin (1 μg/ml) and one (Rov9) was amplified for further study. Rov9 cells were grown at 37°C in 6% CO2 in MEM supplemented with 10% FBS and were usually split at a one-fourth dilution every week.

Immunocytochemistry and Immunoblot Analysis. Immunofluorescence analysis on living Rov9 cells was performed at 4°C, with
4F2 anti-PrP mAbs (31). Fixed cells (10 min at room temperature in PBS containing 4% paraformaldehyde and 4% sucrose) were permeabilized (3 min with 0.1% Triton X-100), incubated sequentially with 4F2 and anti-mouse IgG alkaline phosphatase-conjugated antibodies. Bound antibodies were visualized with Fast Red TR/Naphthol AS-MX (Sigma).

For immunoblot analysis of inoculated cell cultures, proteins from cell lysates were either methanol-precipitated or digested with PK for 2 h at 37°C (2 μg of PK for 500 μg of protein, i.e., 4–6 μg of PK per ml of cell lysate). Pefabloc (4 mM) was added and aggregated PK-resistant PrP was collected by centrifugation at 13,000 rpm for 20 min at room temperature. Pellets from methanol precipitation and PK-treated lysates were resuspended in sample buffer, subjected to SDS/PAGE electrophoresis, and transferred to nitrocellulose membranes. PrP was visualized either with 142 mAbs (32) or 4F2, which does not recognize NH2-terminally truncated abnormal PrP in PK-treated cell lysates. Western blots were revealed with an enhanced chemiluminescence detection system (ECL, Amersham Pharmacia).

**Preparation of Inocula.** PG127 (PG127/98, Veterinary Laboratory Agency, U.K.) and LA404 [954044, Institut National de la Recherche Agronomique (INRA), Jouy-en-Josas, France] isolates are from VRQ-genotyped sheep affected by natural scrapie. Infected sheep brains were homogenized at 10% (wt/vol) in a sterile 5% glucose solution. These two sheep isolates also have been transmitted to Prnpnull transgenic mice expressing the VRQ allele of ovine PrP (TgOv mice, see below for description). The resulting material was used as an alternative source of inoculum, as specified. Extracts from inoculated Rov9 cultures were prepared by scraping cells into PBS, pelleting them by centrifugation, and resuspending the cell pellets in a sterile 5% glucose solution. After four freezing-thawing cycles, suspensions were sonicated for 1–2 min in a cup-horn apparatus before being inoculated to cells or transgenic mice.

**Isolation of PrPres From Infected Brains.** Brain homogenates (typically 200 μl of 10%) were digested for 1 h with 10 μg/ml PK, and the reactions were stopped with 4 mM Pefabloc. After addition of 10% sarcosyl and 10 mM Tris-HCl (pH 7.4), samples were incubated for 15 min at room temperature. They were then centrifuged at 245,000 × g for 30–45 min at 20°C on 10% sucrose cushions. Pelleted material was resuspended in sample buffer and analyzed by immunoblotting.

**Ex Vivo Infection of Rov9 Cells.** All of the brain homogenates used for cell inoculation were heated at 80°C for 20 min and sonicated for 1–2 min. Confluent Rov9 monolayers (grown in single wells of 12-well plates for 2 days in the presence of 1 μg/ml doxycycline (dox) were overlaid with 500 μl of culture medium containing 2.5% (wt/vol) of brain homogenate. Six hours later, 500 μl of culture medium was added and the cultures were incubated for 2 days. The supernatant was then removed, and the cultures were rinsed once with PBS and left for 2.5 days in regular culture medium before being split into two 25-cm² flasks. One week later, one flask was added and grown for 1–2 min in Triton-DOC lysis buffer (50 mM Tris-HCl, pH 7.4/0.5% Triton X-100/0.5% sodium deoxycholate). Lysates were clarified (2,000 rpm, 1 min) and stored at −20°C.

**In Situ PrPres Detection.** Paraffin inclusions of trypsinized, infected and mock-infected Rov9 cells were performed by using a cell block preparation system (Cytoblock, Shandon, Pittsburgh) and then treated as described (33). In brief, sections (2 μm) were mounted and dried overnight at 56°C before being deparaffinized and rehydrated. Slides were first incubated in 98% formic acid for 30 min, followed by 5 min of PK treatment (5 μg/ml at 37°C, and then autoclaved for 30 min at 121°C in 10 mM citrate buffer (pH 6.1) and incubated with 20% normal goat serum for 20 min. PrP immunolabeling was carried by using 8G8 mAbs (31). Biotinylated antibodies were applied as secondary antibodies, and the streptavidin-biotinylated peroxidase complex was used for amplification. Revelation was performed by using diaminobenzidin. Nucleus counterstain was achieved with Mayer’s hematoxylin.

**Mouse Bioassay.** The in vivo infectivity assays were performed on TgOv hemizygous for the ovine Prnp gene (VRQ allele) and nullizygous for the mouse Prnp gene (Prnpnull). Such mice were reported by some of us to be more susceptible to natural sheep scrapie than conventional mice (J.L.V., D.V., and H.L., unpublished results). The tg30l line used in these experiments carries a large DNA fragment isolated from an ovine bacterial artificial chromosome library, and the expression levels of ovine PrP were ≈8-fold those observed in sheep brain. Animals (≈6 wk old) were infected intracerebrally with 20 μl of inoculum. Inoculated mice were examined for neurological dysfunction every 2 days and then daily once clinical signs of scrapie were detected. Most of the diseased animals were killed when the death was imminent, i.e., within 1 wk after the onset of symptoms in this model. The brain of each diseased animal was taken and examined for the presence of PrPres by immunoblotting. Some brains were subjected to histologic examination so as to confirm the diagnosis of scrapie (data not shown).

**Results**

**Inducible Expression of Ovine PrP in Rov9 Cells.** The susceptibility of sheep to scrapie is strongly determined by Prnp, the host gene for PrP. The V136P R154Q T171 allele of PrP (where V, R, and Q stand for valine, arginine, and glutamine, respectively) confers high susceptibility and short incubation time to sheep naturally exposed to scrapie whereas the A136R S154R T171 allele (A for alanine) is associated with an absolute clinical resistance to the disease (11). In a search for cellular models infectable by sheep scrapie agent, we have used the tetracycline-inducible (tet-on) system (34) to achieve regulated, high-level expression of the ovine PrP (VRQ allele). After transfection of several, including ovine brain-derived (35), cell lines, a strong inducible expression of ovine PrP was obtained in most of the clones derived from a rabbit kidney epithelial cell line (RK13). Data obtained with a representative clone (Rov9) are presented in this paper. The dox-induced Rov9 cells synthesized highly glycosylated PrP at levels close to those seen in sheep brain (Fig. 1 A). No PrP could be detected in unstimulated Rov9 cells (Fig. 1 A), indicating that expression of endogenous, rabbit PrP was very low in these cells. Up to 50% of the cells within induced Rov9 cell monolayers synthesized PrP at a high level (Fig. 1 B and C) and expressed it at the outer membrane (Fig. 1 D).

**PrPres Detection in Rov9 Cells Inoculated With Sheep Scrapie Agent.** Rov9 cells were inoculated with an isolate issued from a naturally scrapie-affected sheep homozygous for the VRQ allele (PG127, Veterinary Laboratory Agency, U.K.). After incubation with infectious brain homogenate, Rov9 cell monolayers were rinsed and serially passaged. The cultures were then checked periodically for abnormal protease-resistant PrP (PrPres), the only known molecular marker of prion propagation. PrPres was readily detected in inoculated, induced Rov9 cells (Fig. 2 A). However, PrPres was not observed in inoculated Rov9 cells expressing low levels of PrP (not induced) or in unoinoculated, induced Rov9 cultures. PrPres appeared to accumulate at increasing levels through serial passages of the infected cultures (Fig. 2 B), reaching a maximum at passages 14–18 postinoculation (p.i.). The level of PK resistance of Rov9-generated abnormal PrP was tested (Fig. 2 C), and it was found to be high enough to compare to that from infected tissues. Interestingly, sheep
Sheep Scrapie Replication in Inoculated Rov9 Cells. To assess whether infectivity was associated with PrPres-producing Rov9 cells, fresh cultures were inoculated with cell extracts from infected Rov9 cultures. The detection of newly accumulated abnormal PrP indicates that the PrPres-containing cell extracts induced PrP conversion in recipient cells (Fig. 3A). Next, inoculated cultures were bioassayed in TgOv mice (see Materials and Methods), which are more susceptible than conventional mice to sheep scrapie (J.L.V., D.V., and H.L., unpublished results). Extracts from inoculated Rov9 cultures (either PrPres positive or negative, depending on the dox-dependent level of ovine PrP cell expression) and from inoculated brain- and Rov9-derived PrPres showed distinct glycosylation profile and electrophoretic mobility (Fig. 2D). This finding is in agreement with the observation that the molecular characteristics of PrPres, initially regarded as strain-specific (36), also can depend on the tissue producing the abnormal PrP (37, 38). Altogether, these data led to the conclusion that PrPres was actually produced de novo by infected Rov9 cells and did not originate from residual inoculum.

The proportion of PrPres-producing cells was estimated by using in situ detection of abnormal PrP. Although no labeling was seen in mock-infected cells (Fig. 2E), intense PrPres deposits were observed in at least 30% of the cells of the infected cultures (Fig. 2F). Notwithstanding, this substantial intracellular accumulation of PrPres in a large fraction of the cell population, uncloned infected cultures have been passaged for months, with no obvious loss of viability, alteration of cell morphology, or decline of PrPres accumulation. Infected Rov9 cells fully retained their infected status upon storage in liquid nitrogen (data not shown). The PG127 sheep isolate, passaged once in “ovinized” transgenic mice (TgOv mice, expressing the VRQ allele, see Materials and Methods), was also used as an alternative source of infectious agent. The infection of Rov9 cells proved to be highly reproducible because all of the experiments done so far were successful (n = 21, including inocula from either sheep or TgOv mice). The observed permissiveness of Rov9 cells to infection was not restricted to a single scrapie isolate. LA404 (from INRA) is an isolate from sheep homozygous for the VRQ allele, with biological properties clearly different from PG127 when transmitted to TgOv mice (J.L.V., D.V., and H.L., unpublished results). The LA404 isolate passaged once in TgOv mice also proved to be infectious for Rov9 cells, based on detection of newly accumulated PrPres (Fig. 3A). Whatever the inocula used for infection was Rov9-derived PrPres showed similar electrophoretic patterns (Fig. 3A).
**Discussion**

In this study, we have demonstrated the efficient propagation of ovine prions in cultured cells from a different species. These findings are unique in several respects. Prions from a natural TSE (i.e., without previous experimental adaptation to rodents) were propagated without resorting to animal inoculation, and thus permitting their study at the cellular level. Moreover, we have provided evidence that expression of ovine PrP in an otherwise refractory cell line may be sufficient to allow the species barrier to be crossed *ex vivo*. Whether a similar rationale could apply to the development of the urgently needed bovine and human cellular models is currently being examined. Among the perspectives offered by such models is their use as a rapid bioassay for prions. Experiments are in progress to address the sensitivity of Rov9 cells to sheep scrapie.

In transgenic mice and TSE-infected cultures, expression of an additional and distinct PrP can slow down the replication and/or the propagation of the scrapie agent (7, 39). This has been proposed to be due to the binding of the heterologous PrP to PrPres and the subsequent inhibition of further conversion of PrP in the abnormal isoform, as revealed by cell-free conversion analysis (40). As expression of endogenous rabbit PrP was found undetectable in Rov9 cells, one possible factor that may have contributed for the crossing of the species barrier and the efficient cell transmission of sheep scrapie to Rov9 could be the high ratio of ovine PrP vs. endogenous rabbit PrP.

The influence of PrP expression levels on the susceptibility to TSE is a well documented phenomenon, as evidenced by PrP overexpression in transgenic mice that often results in a marked reduction of the incubation time (8, 9). In a murine TSE cell culture model, it has been proposed that transmission of TSE agents might be improved by heightening of the PrP expression level through transfection (41). By using the cell line described here, the ability to induce elevated levels of *Prnp* gene expression through dox stimulation has allowed us to formally demonstrate this point. Indeed, the PrP expression level was found to have a critical effect on the transmission rate (100%) of sheep scrapie to Rov9 cells (as assessed by the biochemical detection of abnormal PrP) and on the efficiency of infectivity propagation (thousands-fold higher in the presence of dox). The availability of cell clones combining permissivity and regulatable prion protein expression may provide a unique opportunity to further elucidate the events underlying the establishment and/or maintenance of the infected status.

Our data raise the question of whether PrP expression per se would confer susceptibility to any given cell type. This possibility seems unlikely in view of the published data. Indeed, ectopic PrP expression in transgenic mice has resulted in mouse tissues, which do not replicate prions despite high levels of PrP (42). Moreover, marked differences in susceptibility to infection were recently observed among N2a sublines (43). These were apparently unrelated to PrP levels, suggesting the implication of additional factors for efficient prion replication. Our observation, together with a 25-yr-old report describing the infection of murine fibroblasts (44), supports the view that such cofactors are unlikely to be restricted to neuronal or lymphoreticular cells, which are so far the only recognized targets for prion replication. It is tempting to speculate that

---

**Table 1. Bioassay of ovine scrapie-infected Rov9 cells in transgenic mice expressing the VRQ allele of ovine PrP (TgOv mice)**

<table>
<thead>
<tr>
<th>Inoculum*</th>
<th>Survival time (n/nu)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain homogenate 10%</td>
<td>59 ± 1.2 (6/6)</td>
</tr>
<tr>
<td>Brain homogenate 0.1%</td>
<td>71 ± 1.8 (6/6)</td>
</tr>
<tr>
<td>Infected RK13 cells p8</td>
<td>&gt;240 (0/6)</td>
</tr>
<tr>
<td>Infected Rov9 (+ dox) p6</td>
<td>65 ± 1.9 (6/6)</td>
</tr>
<tr>
<td>Infected Rov9 (+ dox) p24</td>
<td>65 ± 0.9 (5/5)</td>
</tr>
<tr>
<td>Infected Rov9 (+ dox) p24 × 10⁻⁴</td>
<td>83 ± 1.5 (5/5)</td>
</tr>
<tr>
<td>Infected Rov9 (– dox) p6</td>
<td>92 ± 3 (6/6)</td>
</tr>
<tr>
<td>Mock-infected Rov9 (+ dox) p12</td>
<td>&gt;180 (0/5)</td>
</tr>
</tbody>
</table>

*Infected dox-induced (– dox), infected untreated (– dox), and mock-infected (+ dox) Rov9 cells were tested at the indicated passage (p). The inoculated parental RK13 cells, expressing no ovine PrP, were assayed at 8 passages p.i.

The brain homogenate (PG127 sheep isolate passaged once in TgOv mice) was used to infect the cultures was bioassayed in parallel. Each animal was inoculated intracerebrally with 20 μl of either one of the following materials: cell extract from infected Rov9 and RK13 cultures, undiluted (3 × 10⁶ cells per mouse) or 10⁴-fold diluted (3 × 10⁵ cells per mouse); or brain homogenate at the indicated dilution.

†Mean days to death ± SEM; n: number of terminally ill animals; nu: number of animals inoculated.
some features shared by neurons and epithelial cells might be involved in their ability to replicate prions. The nervous system is developmentally derived from an epithelium and both neurons and epithelial cells are polarized (45). Similar mechanisms are responsible for the polarized sorting of at least some proteins in neurons and epithelial cells (46). In epithelial cells, most of the glycosyl–phosphatidylinositol-anchored proteins are usually sorted in a polarized manner (47). Although the precise localization of PrP on epithelial cell surface has not been determined yet, evidence has been found for the presence of PrP in specific membrane domains in cultured neurons (48). Further studies should aim at determining the sorting of PrP in Rov9 cells.


In several species, including humans, it is well established that PrP polymorphism affects susceptibility to TSE (10–13), although the mechanisms involved are still unknown. In sheep, the notion that PrP derived from certain alleles might be more efficiently converted to abnormal PrP than others recently has gained support from cell-free conversion experiments in which susceptible PrP alleles showed a greater propensity to be converted than the resistant ones (56). One current limitation of the assay is that the relation between any newly converted PrPres and infectivity cannot be established. In contrast, infectivity produced in Rov9 cells can readily be quantified through bioassay into TgOv mice. Hence, we believe that this ex vivo assay should allow a more accurate assessment of the influence of PrP allelic variants on the transmission of prion diseases. More generally, engineering of permissive cells with regulatable genes encoding PrPs of a specified sequence may represent a promising strategy to further explore, at a cellular level, important aspects of TSE diseases, including that of interspecific transmission.

We thank M. Dawson (Central Veterinary Laboratory/Veterinary Laboratory Agency, U.K.) and J. M. Elsen, and F. Eychenne (Institut National de la Recherche Agronomique/Station d’Amélioration Génétique des Animaux, France) for the kind gift of sheep isolates PG127 and LA404, respectively. We also acknowledge M. H. Grosh for 42 antibodies and J. Grassi (Service de Pharmacologie et d’Immunologie/Commissariat à l’Energie Atomique) for providing 4F2 and 8G8 antibodies. We are grateful to the members of the Service de Neurologie et d’Immunologie Clinique et Experimental (Commissariat à l’Energie Atomique, Fontenay aux Roses, France) for teaching us some basic, “TSE-specific” skills. We thank C. La Bonnardière, J. A. Gingrich, and L. V. Ronco for critical reading of the manuscript and M. Nezonze for the artwork. This work was partially supported by grants from the French government (CI-ESST) and from the European Union (Biotech PL570604).